|
MRPL44 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 7.39770023017172E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
6.86350000167479E-08 |
| Normal-vs-Stage2 |
1.442840E-03 |
| Normal-vs-Stage3 |
5.55440005101104E-09 |
| Normal-vs-Stage4 |
1.74009695541599E-11 |
| Stage1-vs-Stage2 |
9.691600E-01 |
| Stage1-vs-Stage3 |
9.807800E-02 |
| Stage1-vs-Stage4 |
1.017790E-03 |
| Stage2-vs-Stage3 |
2.910400E-01 |
| Stage2-vs-Stage4 |
3.753500E-02 |
| Stage3-vs-Stage4 |
1.209580E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.46849998827747E-09 |
| Normal-vs-AfricanAmerican |
2.12219999999874E-05 |
| Normal-vs-Asian |
2.380099999999E-05 |
| Caucasian-vs-AfricanAmerican |
9.016600E-01 |
| Caucasian-vs-Asian |
8.847600E-01 |
| AfricanAmerican-vs-Asian |
8.319000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.65780000230365E-08 |
| Normal-vs-Female |
2.14939999132469E-09 |
| Male-vs-Female |
6.292800E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.86079999964228E-07 |
| Normal-vs-Age(41-60Yrs) |
3.23850002370563E-09 |
| Normal-vs-Age(61-80Yrs) |
1.19770000028829E-07 |
| Normal-vs-Age(81-100Yrs) |
1.129630E-01 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.614200E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.087600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
7.695800E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.494400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
9.978000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
9.841200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
2.178200E-01 |
| Classical-VS-Follicular |
9.863400E-01 |
| Classical-VS-Other |
5.900200E-01 |
| Classical-VS-Normal |
3.24630000658743E-09 |
| Tall-VS-Follicular |
2.740400E-01 |
| Tall-VS-Other |
8.548400E-01 |
| Tall-VS-Normal |
7.98560000347948E-08 |
| Follicular-VS-Other |
5.218200E-01 |
| Follicular-VS-Normal |
3.93180000000104E-05 |
| Other-VS-Normal |
1.031360E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
8.16120000468601E-08 |
| Normal-vs-N1 |
3.83409970439175E-10 |
| N0-vs-N1 |
1.556960E-03 |
|
|
